-
-
-
-
-
-
-
Atrium Therapeutics receives $15 million milestone from Bristol Myers Squibb
-
-
-
-
-
-
-
TD Cowen Reiterates Hold Rating on Avidity Biosciences (RNA)
-
-
-
-
-
-
-
Leerink Partners Downgrades Avidity Biosciences (RNA) to Market Perform
-
-
-
-
-
-
-
Novartis to acquire Avidity Biosciences for $12 billion or $72 per share cash
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Avidity Biosciences (RNA)
-
-
-
-
-
-
-
Prosensa Holding N.V. (RNA) Misses Q1 EPS by 2c
-
479,042 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


